| Primary |
| Product Used For Unknown Indication |
26.3% |
| Urinary Tract Infection |
21.1% |
| Staphylococcal Infection |
7.7% |
| Sinusitis |
6.1% |
| Drug Use For Unknown Indication |
5.4% |
| Cellulitis |
4.7% |
| Infection |
4.7% |
| Cystitis |
4.0% |
| Hypertension |
2.6% |
| Prophylaxis |
2.6% |
| B Precursor Type Acute Leukaemia |
1.9% |
| Hiv Infection |
1.9% |
| Type 2 Diabetes Mellitus |
1.9% |
| Acne |
1.4% |
| Disseminated Tuberculosis |
1.4% |
| Pneumocystis Jiroveci Pneumonia |
1.4% |
| Skin Infection |
1.4% |
| Ear Infection |
1.2% |
| Glioblastoma Multiforme |
1.2% |
| Multiple Myeloma |
1.2% |
|
| Stevens-johnson Syndrome |
14.9% |
| Rash |
9.1% |
| Vomiting |
9.1% |
| Urticaria |
7.5% |
| Renal Failure Acute |
6.6% |
| Toxic Epidermal Necrolysis |
6.6% |
| Pyrexia |
5.4% |
| Thrombocytopenia |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Drug Hypersensitivity |
3.7% |
| Renal Failure |
3.7% |
| Weight Decreased |
3.7% |
| Tremor |
3.3% |
| Rash Generalised |
2.9% |
| Viral Infection |
2.9% |
| Pruritus |
2.5% |
| Hyperkalaemia |
2.1% |
| Rash Erythematous |
2.1% |
| Swelling Face |
2.1% |
| Anaphylactic Reaction |
1.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
25.3% |
| Product Used For Unknown Indication |
23.5% |
| Hiv Infection |
18.1% |
| Prophylaxis |
4.8% |
| Hypertension |
3.7% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Tuberculosis |
2.3% |
| Renal Transplant |
2.1% |
| Antifungal Prophylaxis |
2.1% |
| Urinary Tract Infection |
1.9% |
| Pneumocystis Jiroveci Pneumonia |
1.5% |
| Rheumatoid Arthritis |
1.5% |
| Infection |
1.4% |
| Pain |
1.3% |
| Multiple Myeloma |
1.2% |
| Acquired Immunodeficiency Syndrome |
1.2% |
| Mycobacterium Avium Complex Infection |
1.2% |
| Infection Prophylaxis |
1.1% |
| Pyrexia |
1.1% |
| Pneumonia |
1.0% |
|
| Drug Hypersensitivity |
13.5% |
| Thrombocytopenia |
11.2% |
| Vomiting |
8.9% |
| Stevens-johnson Syndrome |
7.0% |
| Pyrexia |
6.1% |
| Renal Failure Acute |
5.4% |
| Neutropenia |
4.8% |
| Toxic Skin Eruption |
4.8% |
| Pancytopenia |
4.5% |
| Rash |
4.1% |
| Renal Failure |
3.9% |
| Weight Decreased |
3.8% |
| White Blood Cell Count Decreased |
3.7% |
| Toxic Epidermal Necrolysis |
3.5% |
| Urticaria |
3.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.0% |
| Rash Maculo-papular |
2.5% |
| Agranulocytosis |
2.1% |
| Cytolytic Hepatitis |
2.1% |
| Urinary Tract Infection |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
23.6% |
| Drug Use For Unknown Indication |
18.2% |
| Hiv Infection |
17.5% |
| Prophylaxis |
7.5% |
| Multiple Myeloma |
5.1% |
| Renal Transplant |
3.0% |
| Hypertension |
2.9% |
| Pain |
2.6% |
| Acute Lymphocytic Leukaemia |
2.6% |
| Antifungal Prophylaxis |
2.2% |
| Prophylaxis Against Transplant Rejection |
2.2% |
| Diffuse Large B-cell Lymphoma |
2.1% |
| Chronic Lymphocytic Leukaemia |
2.0% |
| Infection Prophylaxis |
1.7% |
| Diabetes Mellitus |
1.4% |
| Antibiotic Prophylaxis |
1.3% |
| Rheumatoid Arthritis |
1.1% |
| Depression |
1.1% |
| Nausea |
1.1% |
| Antiviral Prophylaxis |
1.0% |
|
| Vomiting |
17.3% |
| Pyrexia |
8.7% |
| Weight Decreased |
8.2% |
| Thrombocytopenia |
7.2% |
| White Blood Cell Count Decreased |
6.2% |
| Renal Failure Acute |
5.2% |
| Urinary Tract Infection |
4.8% |
| Death |
4.5% |
| Renal Failure |
4.3% |
| Pneumonia |
4.3% |
| Sepsis |
4.0% |
| Pulmonary Embolism |
3.5% |
| Weight Increased |
3.3% |
| Septic Shock |
3.2% |
| Respiratory Failure |
2.9% |
| Rash |
2.9% |
| Pancytopenia |
2.6% |
| Tremor |
2.5% |
| Neutropenia |
2.4% |
| Febrile Neutropenia |
2.0% |
|
| Interacting |
| Product Used For Unknown Indication |
34.4% |
| Drug Use For Unknown Indication |
9.3% |
| Hypertension |
6.1% |
| Urinary Tract Infection |
5.7% |
| Hiv Test Positive |
5.0% |
| Convulsion |
4.3% |
| Unevaluable Event |
4.3% |
| Hiv Infection |
3.6% |
| Nephrotic Syndrome |
3.6% |
| Rheumatoid Arthritis |
3.2% |
| Chemotherapy |
2.9% |
| Arrhythmia |
2.5% |
| Acquired Immunodeficiency Syndrome |
2.2% |
| Blood Pressure |
2.2% |
| Bone Disorder |
2.2% |
| Implant Site Thrombosis |
2.2% |
| Blood Pressure Abnormal |
1.8% |
| Ingrowing Nail |
1.8% |
| Cervix Carcinoma |
1.4% |
| Cytomegalovirus Chorioretinitis |
1.4% |
|
| Drug Interaction |
11.4% |
| Hepatic Enzyme Increased |
9.1% |
| Prothrombin Level Decreased |
9.1% |
| Hyponatraemia |
6.8% |
| Viral Infection |
6.8% |
| Weight Decreased |
6.8% |
| Nasopharyngitis |
4.5% |
| Premature Labour |
4.5% |
| Pyrexia |
4.5% |
| Rash |
4.5% |
| Renal Tubular Necrosis |
4.5% |
| Unevaluable Event |
4.5% |
| Urinary Tract Infection |
4.5% |
| Vomiting |
4.5% |
| Agranulocytosis |
2.3% |
| Chest Pain |
2.3% |
| Dizziness |
2.3% |
| Drug Toxicity |
2.3% |
| Eye Movement Disorder |
2.3% |
| Gastrointestinal Haemorrhage |
2.3% |
|
